Innoviva Stock

Innoviva EBIT

The EBIT of Innoviva (INVA) as of Aug 7, 2026 is 163.75 M USD. In the previous year, EBIT was 59.60 M USD — a change of 174.75% (higher).

EBIT

163.75 MUSD

YoY

174.75%

Last updated:

In 2026, Innoviva's EBIT was 163.75 M USD, a 174.75% increase from the 59.60 M USD EBIT recorded in the previous year.

The Innoviva EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
116.90 base
Jan 1, 2024
59.60 base
Jan 1, 2025
163.75 base
Jan 1, 2026 (e)
314.98 base
Jan 1, 2027 (e)
346.03 base
Jan 1, 2028 (e)
365.78 base
Jan 1, 2029 (e)
406.72 base
Jan 1, 2030 (e)
458.37 base
YEAREBIT (M USD)
2030 est 458.37
2029 est 406.72
2028 est 365.78
2027 est 346.03
2026 est 314.98
2025 163.75
2024 59.60
2023 116.90
2022 216.42
2021 392.33
2020 303.16
2019 246.36
2018 238.25
2017 183.60
2016 108.99
2015 31.58
2014 -33.93
2013 -28.80
2012 -13.00
2011 -109.74
2010 -78.32
2009 -80.22
2008 -87.79
2007 -168.57
2006 -179.17
Access this data via the Eulerpool API

Innoviva Revenue

Innoviva Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
310.46 M USD
116.90 M USD
179.72 M USD
Jan 1, 2024
358.71 M USD
59.60 M USD
23.39 M USD
Jan 1, 2025
425.13 M USD
163.75 M USD
271.17 M USD
Jan 1, 2026 (e)
440.56 M USD
314.98 M USD
266.78 M USD
Jan 1, 2027 (e)
483.98 M USD
346.03 M USD
167.48 M USD
Jan 1, 2028 (e)
511.60 M USD
365.78 M USD
153.28 M USD
Jan 1, 2029 (e)
568.87 M USD
406.72 M USD
141.32 M USD
Jan 1, 2030 (e)
641.11 M USD
458.37 M USD
156.27 M USD

Innoviva Margins

Innoviva stock margins

The Innoviva margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innoviva. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innoviva.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
86.27 %
37.65 %
57.89 %
Jan 1, 2024
89.80 %
16.61 %
6.52 %
Jan 1, 2025
72.33 %
38.52 %
63.78 %
Jan 1, 2026 (e)
72.33 %
71.50 %
60.56 %
Jan 1, 2027 (e)
72.33 %
71.50 %
34.61 %
Jan 1, 2028 (e)
72.33 %
71.50 %
29.96 %
Jan 1, 2029 (e)
72.33 %
71.50 %
24.84 %
Jan 1, 2030 (e)
72.33 %
71.50 %
24.37 %

Innoviva Stock analysis

What does Innoviva do? Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Innoviva's EBIT

Innoviva's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Innoviva's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Innoviva's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Innoviva’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Innoviva stock

EBIT of Innoviva is 163.75 M USD in 2026.

EBIT of Innoviva changed from 59.60 M USD to 163.75 M USD, representing a 174.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Innoviva since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Innoviva historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Innoviva

All Key Metrics — Innoviva